𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-yield anthocyanin biosynthesis in engineered Escherichia coli

✍ Scribed by Yajun Yan; Zhen Li; Mattheos A.G. Koffas


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
243 KB
Volume
100
Category
Article
ISSN
0006-3592

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Anthocyanins are red, purple, or blue plant water‐soluble pigments. In the past two decades, anthocyanins have received extensive studies for their anti‐oxidative, anti‐inflammatory, anti‐cancer, anti‐obesity, anti‐diabetic, and cardioprotective properties. In the present study, anthocyanin biosynthetic enzymes from different plant species were characterized and employed for pathway construction leading from inexpensive precursors such as flavanones and flavan‐3‐ols to anthocyanins in Escherichia coli. The recombinant E. coli cells successfully achieved milligram level production of two anthocyanins, pelargonidin 3‐O‐glucoside (0.98 mg/L) and cyanidin 3‐O‐gluside (2.07 mg/L) from their respective flavanone precursors naringenin and eriodictyol. Cyanidin 3‐O‐glucoside was produced at even higher yields (16.1 mg/L) from its flavan‐3‐ol, (+)‐catechin precursor. Further studies demonstrated that availability of the glucosyl donor, UDP‐glucose, was the key metabolic limitation, while product instability at normal pH was also identified as a barrier for production improvement. Therefore, various optimization strategies were employed for enhancing the homogenous synthesis of UDP‐glucose in the host cells while at the same time stabilizing the final anthocyanin product. Such optimizations included culture medium pH adjustment, the creation of fusion proteins and the rational manipulation of E. coli metabolic network for improving the intracellular UDP‐glucose metabolic pool. As a result, production of pelargonidin 3‐O‐glucoside at 78.9 mg/L and cyanidin 3‐O‐glucoside at 70.7 mg/L was achieved from their precursor flavan‐3‐ols without supplementation with extracellular UDP‐glucose. These results demonstrate the efficient production of the core anthocyanins for the first time and open the possibility for their commercialization for pharmaceutical and nutraceutical applications. Biotechnol. Bioeng. 2008;100: 126–140. © 2007 Wiley Periodicals, Inc.


📜 SIMILAR VOLUMES


Propionate-regulated high-yield protein
✍ Sung Kuk Lee; Jay D. Keasling 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

## Abstract A new expression system containing the __Salmonella enterica prpBCDE__ promoter (P~__prpB__~) responsible for expression of the propionate catabolic genes (__prp BCDE__) and __prpR__ encoding the positive regulator of this promoter has been developed and tested. The main features of the

Engineered isoprenoid pathway enhances a
✍ Chia-Wei Wang; Min-Kyu Oh; James C. Liao 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

The isoprenoid pathway is a versatile biosynthetic network leading to over 23,000 compounds. Similar to other biosynthetic pathways, the production of isoprenoids in microorganisms is controlled by the supply of precursors, among other factors. To engineer a host that has the capability to supply ge

Eliminating side products and increasing
✍ Kaemwich Jantama; Xueli Zhang; J.C. Moore; K.T. Shanmugam; S.A. Svoronos; L.O. I 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

## Abstract Derivatives of __Escherichia coli__ C were previously described for succinate production by combining the deletion of genes that disrupt fermentation pathways for alternative products (__ldhA::FRT, adhE::FRT, ackA::FRT, focA‐pflB::FRT, mgsA, poxB__) with growth‐based selection for incre

Rationally Engineered Total Biosynthesis
✍ Kenji Watanabe; Kinya Hotta; Alex P. Praseuth; Mark Searcey; Clay C. C. Wang; Hi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB 👁 1 views

Quinomycin antibiotics, such as echinomycin (1) and triostin A (2; [1] Scheme 1), are nonribosomally synthesized peptides char-Scheme 1. Structures of the natural quinomycin antibiotics echinomycin (1) and triostin A (2), and the synthetic antibiotic TANDEM (3).